

SUPPLEMENTARY TABLE S3. MULTIPLE LINEAR REGRESSION OF GLOBAL EFFICIENCY, CLUSTERING COEFFICIENT (γ), AND SMALL-WORLD INDEX (σ) ON CBZ/OXC

<i>Covariate</i>	<i>Coefficient (95% confidence interval)</i>		
	<i>GE</i>	γ	σ
Gender	-0.004 (-0.040, 0.032)	0.01 (-0.41, 0.43)	0.13 (-0.22, 0.47)
Age	0.0002 (-0.002, 0.002)	-0.01 (-0.04, 0.02)	0.002 (-0.02, 0.02)
Epilepsy duration (years)	0.0006 (-0.0006, 0.002)	0.01 (-0.009, 0.03)	0.005 (-0.006, 0.02)
+CBZ/OXC	0.012 (-0.022, 0.046)	-0.03 (-0.41, 0.36)	0.15 (-0.16, 0.45)
TLE laterality (+ RTLE)	0.002 (-0.034, 0.038)	-0.31 (-0.82, 0.19)	-0.27 (-0.61, 0.06)
Drug load	0.006 (-0.006, 0.019)	0.16 (-0.04, 0.35)	0.12 (0.003, 0.24)

Omnibus hypothesis was not significant for these models. Parameter estimates and confidence intervals are included only for reference. CBZ/OXC, carbamazepine and oxcarbazepine; GE, global efficiency; RTLE, right temporal lobe epilepsy.